Fathom Therapeutics focuses on drug design by harnessing biomolecular motion to develop therapeutics that can reprogram protein function.
Fathom Therapeutics has raised $47.0M in total funding. The most recent round was Series A. The last funding was announced in April 2026.
Fathom Therapeutics's investors include Chemistry, Sutter Hill Ventures, Alexandria Venture Investments, New York Ventures, Bikui Chen.
Fathom Therapeutics is headquartered in New York, United States.
Fathom Therapeutics focuses on drug design by harnessing biomolecular motion to develop therapeutics that can reprogram protein function.
Fathom Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Fathom Therapeutics — Funding & Investors." VCBacked, April 27, 2026, https://www.vcbacked.co/company/fathom-therapeutics. Accessed July 31, 2026.
VCBacked. (2026). Fathom Therapeutics — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/fathom-therapeutics
{{cite web |title=Fathom Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/fathom-therapeutics |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated